Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Neopath's Autopap

This article was originally published in The Gray Sheet

Executive Summary

Neopath's Autopap: Pap smear analysis product as a primary screening device will be reviewed by FDA's Hematology and Pathology Devices Panel on Jan. 28, the company reports. The PMA supplement would allow use of the Autopap to identify certain slides as not requiring a manual evaluation. Following the advisory panel's initial rejection of the supplement in September 1996, Neopath amended the application in August with prospective data from about 31,500 slides. The data show the system to be statistically "superior" to current practice in identifying a range of atypical Pap smears, according to the company. The Autopap currently is approved as a quality control rescreener of slides identified by technicians as negative...



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts